Large pharma companies at World Vaccine Congress Europe 2026

Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website

13 large pharma companies are at World Vaccine Congress Europe 2026 — 42 presentations on the program and 3 with a booth in the exhibit hall. Most represented: Sanofi (8 on the program), GSK (7 on the program), Moderna (6 on the program). 12 of them have their own page in this guide. As of Sep 26, 2026.

All 251 organizations at World Vaccine Congress Europe 2026 →

Showing 1–10 of 13 organizations

Organization	World Vaccine Congress Europe 2026 Attendance
Sanofi Paris, France
sanofi.com Large pharma Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs.	Talk Mon Oct 19 10:45 mRNA-LNP Platform: Screening, Formulation Optimization and Process Improvements Workshop: Platform Technologies Talk Mon Oct 19 11:30 Immunity Takes Care of Your Skin: The Vaccine Reinventing Acne Treatment Workshop: Cancer & Therapeutic Vaccines Talk Mon Oct 19 14:45 Assessing and Monitoring Vaccine Safety in the AI Era Workshop: Vaccine Safety & Access Talk Mon Oct 19 15:30 Advancing Pandemic Preparedness: Pandemic Flu H5 mRNA program Workshop: Biothreats & Disease X Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. with European Medicines Agency, Vaccines Europe, International Vaccine Institute +4 more Platforms & delivery Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. with PATH, McKinsey & Company, AstriVax Talk Wed Oct 21 13:30 Platform leverage in vaccine development: how diversified technologies and adjuvant innovation are reshaping protection for older adults, Respiratory Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. with GSK, Swedish Medical Products Agency, European Medicines Agency
GSK London, United Kingdom
	Panel Mon Oct 19 12:15 Panel: Building Next-Generation Vaccine Platforms: Innovation, Stability, and Scalability Workshop: Platform Technologies · with CEPI, IAVI, Vaccine Analytics +2 more Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with European Medicines Agency, BioNTech, Gates Medical Research Institute +1 more Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. with UK Health Security Agency (UKHSA), CSL Seqirus, University of Oxford +1 more Talk Wed Oct 21 13:15 Advancing European Competitiveness: Innovation in Vaccine Manufacturing Technology through AI, ML, and Modeling Bioprocess & Manufacturing Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. with London School of Hygiene & Tropical Medicine, Novo Nordisk Foundation Initiative for Vaccines and Immunity, European Vaccine Initiative +2 more Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. with Swedish Medical Products Agency, Sanofi, European Medicines Agency
Moderna Cambridge, MA
	Talk Mon Oct 19 14:00 Workshop Leader Workshop: Vaccine Safety & Access Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with GSK, European Medicines Agency, BioNTech +1 more Talk Mon Oct 19 15:15 Moderna’s Clinical Development of Bundibugyo Ebolavirus Vaccine Workshop: Biothreats & Disease X Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. with UK Health Security Agency (UKHSA), PATH, Erasmus MC +1 more Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. with PATH, Baylor College of Medicine, MHRA +2 more Infectious disease & AMR Talk Wed Oct 21 15:15 Moderna’s Influenza Program Respiratory
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company with a vaccine portfolio spanning pneumococcal, RSV, COVID-19 and other infectious diseases.	Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. with European Medicines Agency, Vaccines Europe, International Vaccine Institute +4 more Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. with Eli Lilly, CUNY School of Public Health, European Medicines Agency +1 more Supply, safety & access Talk Wed Oct 21 15:15 A Phase 2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a C. difficile Adjuvanted Vaccine in Healthy Adults AMR & Bacterial Vaccines Talk Wed Oct 21 15:30 Maternal vaccine introduction in LMICs Respiratory
CSL Seqirus
seqirus.com Large pharma CSL's influenza vaccine business, making seasonal and pandemic influenza vaccines, including adjuvanted and cell-based vaccines.	Talk Wed Oct 21 10:45 MF59-adjuvanted cell-derived higher-dose influenza vaccine: Building the Evidence for Influenza Prevention Respiratory Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. with UK Health Security Agency (UKHSA), University of Oxford, GSK +1 more
BioNTech Mainz, Germany
biontech.com Large pharma Develops mRNA vaccines and immunotherapies for infectious diseases and cancer, including the marketed COVID-19 vaccine Comirnaty.	Talk Mon Oct 19 10:15 Multi-Modality approaches in immuno-oncology: navigating regulatory hurdles to shape the future of cancer therapies Workshop: Cancer & Therapeutic Vaccines Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with GSK, European Medicines Agency, Gates Medical Research Institute +1 more Talk Wed Oct 21 12:30 Design and development of mRNA-encoded tuberculosis vaccines AMR & Bacterial Vaccines
Johnson & Johnson New Brunswick, NJ
	Talk Tue Oct 20 14:00 Track Chair Formulation & Bioprocess Talk Tue Oct 20 16:00 Track Chair Formulation & Bioprocess Talk Wed Oct 21 10:30 Results from the Phase 3 E.mbrace study: Exploring the Lack of Efficacy of a 9-Valent Vaccine (ExPEC9V) for the Prevention of Invasive Escherichia coli Disease in Older Adults AMR & Bacterial Vaccines
B BIKEN
Large pharmaSilver sponsor Japanese vaccine maker linked to Osaka University, producing influenza and other vaccines.	Booth Exhibiting at Booth 226 Talk Tue Oct 20 14:30 Research and development of vaccines against Enterovirus D68 Pre-Clinical Development Talk Wed Oct 21 11:30 Phase III Study of an Intranasal Quadrivalent Inactivated Whole Virion Influenza Vaccine in Healthy Japanese Participants Aged 13–64 Years Clinical Trials
Novavax Gaithersburg, MD
novavax.com Large pharmaAssociate sponsor Vaccine company developing protein-based vaccines with its Matrix-M adjuvant, including a marketed COVID-19 vaccine.	Booth Exhibiting (no floor booth listed) Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. with European Medicines Agency, Vaccines Europe, International Vaccine Institute +4 more Platforms & delivery Talk Wed Oct 21 14:00 The Potential of Novavax’s Technology Platform, including Matrix-M® adjuvant Emerging & Infectious Diseases
Boehringer Ingelheim Ingelheim am Rhein, Germany
boehringer-ingelheim.com Large pharma Pharmaceutical company whose animal health business makes livestock and companion-animal vaccines.	Panel Wed Oct 21 11:00 Panel: Rethinking Livestock Vaccination for Emerging Threats How to speed new livestock vaccines against diseases that can jump to people, weighing approval rules, food safety, trade and funding incentives. with World Organisation for Animal Health (WOAH), SciEthiQ, VIDO (Vaccine and Infectious Disease Organization) +1 more Talk Wed Oct 21 13:15 Efficacy of Early Vaccination Against Avian Influenza in Commercial Poultry One Health & Veterinary · with Wageningen University & Research